Celyad scraps one final clinical CAR-T program as clock ticks
Celyad Oncology began the year with hopes that it could garner the first evidence that its off-the-shelf CAR-T approach could lead to much-needed breakthroughs in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
